Why Is HARMONY BIOSCIENCES (HRMY) Stock Up Today?

Harmony Biosciences (HRMY) shares surged 10.10% to $39.20 on August 4, 2026, driven by strong Q2 2026 results and updated guidance. The company reported record net revenue of $261.3 million for the quarter, a 30% year-over-year increase, and reaffirmed its full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion. The stock opened with a 1.1% gap up and reached an intraday high of $39.20 shortly after the market opened.

What Happened

The stock’s sharp rise followed the release of Harmony Biosciences’ Q2 2026 earnings and a Form 8-K filing disclosing results of operations and financial condition. The company also shared initial clinical data for its orexin-2 agonist BP-205, reinforcing its potential best-in-class profile. Earnings per share exceeded estimates, with GAAP EPS at $1.28 versus an expected $0.94. Additionally, the company announced the appointment of Stephen Mollichella as interim CFO. These developments, combined with reaffirmed revenue guidance, contributed to the stock’s strong performance.

What The Data Shows

The stock opened at $35.99 and reached a session high of $39.20 before settling near $39.05. The intraday volume of 0.1 million shares was 0.2 times the 3-month daily average. The stock currently trades within its 52-week range of $25.52 to $40.87, with a market cap of $2.0 billion. The company’s fundamentals show a revenue growth of 20.7% trailing twelve months, a net margin of 16.2%, and a P/E ratio of 14.4. Analysts from Mizuho and HC Wainwright & Co. have maintained positive ratings, with price targets of $51 and $55, respectively.

What To Watch

Harmony Biosciences has already released its Q2 2026 earnings and guidance. Investors should monitor upcoming developments related to its orexin-2 program and the progress of WAKIX toward its $1 billion revenue target. Coverage breadth and any further updates on clinical trials or executive leadership will also be key to watch.